← Back to Search

Nonsteroidal Anti-inflammatory Drug

Aspirin for Cardiovascular Disease (CAPE Trial)

Phase 4
Waitlist Available
Led By Kathryn T Hall, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
healthy, 18-40 years
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at end of treatment 10-14 days the platelets will be activated on the same day as blood collection.
Awards & highlights

CAPE Trial Summary

This trial will examine the role of genetic variation in COMT on platelet function in a blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for 10 ± 3 days. Platelet function will be assessed with platelet aggregometry and by fluorescence-activated cell sorting (FACS) of platelet adhesion molecules P-selectin and GPIIb/IIIa in platelets activated with arachidonic acid, thrombin, collagen, epinephrine and ADP.

CAPE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

CAPE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at end of treatment 10-14 days the platelets will be activated on the same day as blood collection.
This trial's timeline: 3 weeks for screening, Varies for treatment, and at end of treatment 10-14 days the platelets will be activated on the same day as blood collection. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
platelet aggregation
Secondary outcome measures
% expression of P-selectin on resting and activated platelets

CAPE Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: AspirinActive Control1 Intervention
Aspirin (81mg) will be taken orally daily for 10-14 days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,622 Previous Clinical Trials
11,468,712 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,847 Previous Clinical Trials
47,818,191 Total Patients Enrolled
Kathryn T Hall, PhDPrincipal InvestigatorBrigham and Women's Hospital
~9 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top